Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease pathogenesis and treatment

Table 1 Studies comparing rituximab-cyclophosphamide doxorubicin vincristine prednisone vs cyclophosphamide doxorubicin vincristine prednisone for diffuse large B-cell lymphoma primary gastric lymphomas

Ref.		Number of Pts	R-CHOP OS	CHOP OS	R-CHOP PFS	CHOP PFS	Comments
Sohn et al[19], 2012	Double-arm Retrospective Study (R-CHOP vs CHOP as 1st line treatment)	93 (55 R-CHOP, 38 CHOP)	3-yr 84.7% (P > 0.05)	3-yr 94.7% (P > 0.05)	3-yr 81.7% (EFS) (P > 0.05)	3-yr 86% (EFS) (P > 0.05)	CR: (CHOP: 93.9%), (R-CHOP: 92.5%)
Liu et al[62], 2018	Double-arm Retrospective Study (diagnosis: 1973-2000 era vs 2001-2014 era of immuno-CT)	SEER Database 7051 [(4186, 1973-2000), (2865, 2001-2014)	5-yr 53% (P = 0.001)	5-yr 47% (P = 0.001)
Tanaka et al[20], 2012	Single-arm Retrospective Study (R-CHOP)	95	3-yr 91% (localized disease); 3-yr 95% (localized disease); 3-yr 64% (localized disease)		3-yr 91% (localized disease); 3-yr 92% (localized disease); 3-yr 43% (localized disease)		6c. R-CHOP; 3-4 c. R-CHOP plus radiotherapy; R-CHOP ± radiotherapy
Couto et al[17], 2021	Single-arm Retrospective Study (R-CHOP)	101	Not reached		Not reached		80% CR (after 1st line); 54% CR (3 yrs FU)

R-CHOP: Rituximab-cyclophosphamide doxorubicin vincristine prednisone; CHOP: Cyclophosphamide doxorubicin vincristine prednisone; OS: Overall survival; PFS: Progression-free survival; EFS: Event free survival; CR: Complete remission; CT: Computed tomography; FU: Follow-up.